FRMD4A: A Protein with Unique FERM Domain and Potential Drug Target/biomarker Properties

Target Name: FRMD4A

NCBI ID: G55691

FRMD4A

FRMD4A: A Protein with Unique FERM Domain and Potential Drug Target/biomarker Properties

FRMD4A, also known as FERM domain-containing protein 4A (isoform a), is a protein that is expressed in various tissues and cells in the human body. It is a member of the family of ATP-binding proteins, which are known for their ability to regulate cellular processes such as protein synthesis, DNA replication, and cell signaling.

FRMD4A is characterized by its unique FERM domain, which is a protein domain that is composed of 25 amino acids. The FERM domain is responsible for FRMD4A's unique structure and function. This domain is characterized by a long acidic tail that is involved in interactions with various cellular components, as well as a short amino acid residue that is involved in interactions with ATP.

FRMD4A is also characterized by its ability to interact with various cellular signaling pathways. For example, FRMD4A has been shown to interact with the protein p21, which is a hallmark of the T-cell signaling pathway. This interaction between FRMD4A and p21 suggests that FRMD4A may be a potential drug target or biomarker for T-cell-related diseases.

In addition to its potential role in T-cell signaling, FRMD4A has also been shown to interact with the protein p53, which is involved in the regulation of cellular apoptosis (programmed cell death). This interaction between FRMD4A and p53 suggests that FRMD4A may be a potential drug target or biomarker for processes related to cell death, such as cancer.

FRMD4A is also characterized by its ability to interact with various cellular signaling pathways. For example, FRMD4A has been shown to interact with the protein p21, which is a hallmark of the T-cell signaling pathway. This interaction between FRMD4A and p21 suggests that FRMD4A may be a potential drug target or biomarker for T-cell-related diseases.

In addition to its potential role in T-cell signaling, FRMD4A has also been shown to interact with the protein p53, which is involved in the regulation of cellular apoptosis (programmed cell death). This interaction between FRMD4A and p53 suggests that FRMD4A may be a potential drug target or biomarker for processes related to cell death, such as cancer.

FRMD4A is also involved in the regulation of cellular processes such as protein synthesis and DNA replication. It has been shown to interact with various cellular components, including the protein SIRT1, which is involved in the regulation of cellular processes such as DNA replication and stress responses. This interaction between FRMD4A and SIRT1 suggests that FRMD4A may be a potential drug target or biomarker for processes related to cellular stress responses.

In conclusion, FRMD4A is a protein that is characterized by its unique FERM domain and its ability to interact with various cellular signaling pathways. Its ability to interact with T-cell signaling pathways, as well as its potential role in the regulation of cellular processes such as protein synthesis, DNA replication, and cellular stress responses, make FRMD4A a promising candidate for drug development or as a biomarker for T-cell-related diseases and processes related to cell death. Further research is needed to fully understand the role of FRMD4A in cellular processes and its potential as a drug target or biomarker.

Protein Name: FERM Domain Containing 4A

Functions: Scaffolding protein that regulates epithelial cell polarity by connecting ARF6 activation with the PAR3 complex (By similarity). Plays a redundant role with FRMD4B in epithelial polarization (By similarity). May regulate MAPT secretion by activating ARF6-signaling (PubMed:27044754)

The "FRMD4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRMD4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets